BioSpace News Archive

Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease, today announced the closing of its upsized initial public offering of 13,664,704 shares of common stock,

Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that preclinical data for BT7480, a tumor-targeted immune cell agonist (TICA™), and an EphA2/CD137 TICA will be presented during an e-poster session at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced the titles and times of its presentations at the upcoming 35th Annual Meeting of The Society for Immunotherapy of Cancer (SITC 2020) taking place virtually November 9th – 14th.

Wheeler Labs, a company founded by experienced biotech CEO Dr. Jesse McCool, will bring to market a non-invasive, direct-to-patient, at-home COVID-19 test. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201014005257/en/ Experienced biotech CEO Dr. Jesse McCool launches Wheeler Labs (Photo: Bu

TEPEZZA ® (teprotumumab-trbw) Data from the Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease (TED) -- New findings presented during the Academy of Managed Care Pharmacy Nexus 2020 Virtual Meeting showed most patients had at least some improvement in one or more disease parameters for up to one year following TEPEZZA treatment for TED, and are supported by recently announced long-term follow-up data from the Phas

-- Former GRAIL CEO and Roche/Genentech senior executive brings extensive product development and commercialization expertise to liver therapeutics pioneer -- SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Ambys Medicines, a cell and gene therapy company focused on advancing novel treatments to restore and regenerate liver function, today announced the appointment of Jennifer Cook to its Board of Directors. A highly respected biotechnology and

NDA s ubmission is supported by positive data from two Phase 3 studies ( VANISH Program ) in women with vulvovaginal candidiasis (VVC) As a qualified infectious disease product (QIDP) , ibrexafungerp is expected to receive a 6-month priority review following NDA acceptance

Yale University Study Found No Association Between Child Care and the Spread of COVID-19 to Providers; Child Care Aware of America Provides Recommendations for Providers, Parents and Policymakers

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Gilead’s cash tender offer for Immunomedics, Inc. expired at 11:59 p.m. on October 13, 2020. On September 25, 2020, Gilead and Immunomedics filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade

Hancock Jaffe Laboratories, Inc., a developer of medical devices that restore cardiac and vascular health, announced that the first two surgeries for its CoreoGraft first-in-human study are scheduled to take place by the end of October.